G17DT Completed Phase 2 Trials for Malignant Neoplasm of Stomach Treatment

clinicaltrials.gov IdentifierTitleDrugs
NCT02233712Open-label, Dose-finding Study to Determine Antibody Response to G17DT Treatment in Patients With Gastric Cancer.
NCT02450032Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric Cancer
NCT02518529Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients
NCT02521649Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer